Vaccines for covid-19 patients
As part of the COVID-NMA initiative, we are identifying all randomized controlled trials (RCTs) of COVID-19 vaccine.
Below, you can access
- A table with the general characteristics and risk of bias assessment for all RCTs identified.
- A synthesis with forest plots and summary of findings table/evidence profile including phase 2-3 trials. For the vaccine (dose and schedule) evaluated in phase 2-3 trials, results available for the same vaccine (dose and schedule) in phase 1-2 trial will also be included in the synthesis.
Of note: For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.
Treatment comparisons
We report below the forest plots for the main treatment comparisons.
Please choose a Treatment Comparison:
- ChAdOx1 vs MenACWY (University of Oxford/AstraZeneca )
- BNT162b2 vs Placebo (BioNTech/Fosun Pharma/Pfizer )
- mRNA-1273 vs Placebo (ModernaTX)
Last update: 22/01/2021
Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias |
Full description | |
---|---|---|---|---|---|---|---|---|
Intervention 1 | Intervention 2 | |||||||
NCT04412538
Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAMS). Che Y,Clin Infect Dis,2020 Full text Commentary |
Inactivated virus | KMS-1 100 EU D0/14 | Adjuvant | RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in two centres in China | N=750 |
Some concerns Details |
|
KMS-1 150 EU D0/14 | Adjuvant | |||||||
KMS-1 100 EU D0/28 | Adjuvant | |||||||
KMS-1 150 EU D0/28 | Adjuvant | |||||||
NCT04471519 ; CTRI/2020/07/026300
Bharat Biotech Ella R,medRxiv,2020 Full text ; Full text Commentary ; Commentary |
Inactivated virus | 3mcg BBV152 + Algel-IMDG | Adjuvant | RCTphase 1 | Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India | N=375 |
Some concerns Details |
|
6mcg BBV152 + Algel-IMDG | Adjuvant | |||||||
6mcg BBV152 + Algel | Adjuvant | |||||||
NCT04412538
The Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAM) Pu J, MedRxiv, 2020 Full text Commentary ; Commentary |
Inactivated virus | KMS-1 D0/14 | Adjuvant | RCTPhase 1 | Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China. | N=192 |
Some concerns Details |
|
KMS-1 D0/28 | Adjuvant | |||||||
ChiCTR2000031809
Wuhan Institute of Biological Products Co Ltd./Sinopharm Xia S, JAMA, 2020 Full text Commentary |
Inactivated virus | Inactivated 2.5mcg-D0/28/56 | Adjuvant | RCTPhase 1/2 | Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test | N=96 |
Low Details |
|
Inactivated 5mcg-D0/28/56 | Adjuvant | |||||||
Inactivated 10mcg-D0/28/56 | Adjuvant | |||||||
Inactivated 5mcg-D0/14 | Adjuvant | |||||||
Inactivated 5mcg-D0/21 | Adjuvant | |||||||
ChiCTR2000032459
Beijing Institute of Biological Products/Sinopharm Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Inactivated virus | BBIBP-CorV 8mcg | Adjuvant | RCTPhase 2 | Healthy SARS-CoV-2 serology negative adults 18-59 years old and ?60 years old in a single centre in China | N=112 |
Some concerns Details |
|
BBIBP-CorV 4mcg D0/14 | Adjuvant | |||||||
BBIBP-CorV 4mcg D0/21 | Adjuvant | |||||||
BBIBP-CorV 4mcg D0/28 | Adjuvant | |||||||
NCT04352608
Sinovac Zhang Y,Lancet Infect Dis,2020 Full text Commentary |
Inactivated virus | CoronaVac 3 mcg D0/14 | Adjuvant | RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N=600 |
Some concerns Details |
|
CoronaVac 6 mcg D0/14 | Adjuvant | |||||||
CoronaVac 3 mcg D0/28 | Adjuvant | |||||||
CoronaVac 6 mcg D0/28 | Adjuvant |
The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.
We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.